Physician profile
Amy E Hill
NPI 1295208668
$28,756.33
in general payments reported to CMS, 2019-2025
65 companies · $7,003 in 2025
The $7,003 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,975 · 2022: $5,314 · 2023: $4,564 · 2024: $6,900 · 2025: $7,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,211.65 |
| Education | $255.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,831.33 | 2021-2025 | |
| Eisai INC. | $1,368.35 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $1,323.50 | 2021-2025 | |
| Ucb, INC. | $1,185.31 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurocrine Biosciences, INC. | $1,144.85 | 2021-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $1,118.95 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $1,083.72 | 2021-2025 | Xcopri |
| Mdd US Operations, LLC | $1,002.41 | 2022-2025 | Gocovri, Gocovri |
| Catalyst Pharmaceuticals, INC. | $996.97 | 2023-2025 | Fycompa |
| Lundbeck LLC | $961.94 | 2021-2025 | Vyepti, Rexulti |
| Pfizer INC. | $849.42 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $820.86 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $820.81 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $789.90 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $761.72 | 2021-2025 | Aimovig, Prolia, Uplizna |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $665.44 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Janssen Pharmaceuticals, INC | $643.12 | 2021-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $641.43 | 2023-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $638.18 | 2021-2025 | |
| Emd Serono, INC. | $591.95 | 2021-2025 | Mavenclad, Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $567.27 | 2021-2025 | Hyqvia, Trintellix, Gammagard |
| Upsher-Smith Laboratories LLC | $460.07 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $437.90 | 2021-2022 | |
| Janssen Biotech, INC. | $419.20 | 2025 | |
| Alexion Pharmaceuticals, INC. | $408.39 | 2021-2025 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $379.57 | 2021-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $372.50 | 2021-2025 | Nuplazid, Daybue |
| E.R. Squibb & Sons, L.L.C. | $348.38 | 2024-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $332.52 | 2021-2022 | |
| Corium, LLC | $328.55 | 2022-2025 | Azstarys, Adlarity, Adlarity |
| Harmony Biosciences LLC | $284.49 | 2022-2025 | Wakix |
| Allergan, INC. | $265.58 | 2021-2022 | |
| Biogen, INC. | $255.07 | 2021-2025 | Leqembi |
| Amneal Pharmaceuticals LLC | $245.45 | 2021-2025 | Crexont, Rytary |
| Idorsia Pharmaceuticals US INC | $243.43 | 2023-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $242.83 | 2021-2025 | Qelbree, Qelbree |
| Csl Behring | $232.83 | 2022-2025 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $215.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $212.04 | 2021 | |
| Kedrion Biopharma, INC. | $203.43 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Genzyme Corporation | $201.40 | 2021-2023 | |
| Azurity Pharmaceuticals, INC. | $172.48 | 2023-2025 | Horizant, Horizant |
| Grifols USA, LLC | $168.31 | 2021-2025 | Gamunex-C |
| Impel Pharmaceuticals INC. | $167.15 | 2022-2023 | Trudhesa |
| Acorda Therapeutics, INC | $158.37 | 2021-2023 | Inbrija |
| Greenwich Biosciences, INC. | $125.15 | 2021 | |
| Adamas Pharmaceuticals, INC. | $123.45 | 2021 | |
| Genentech USA, INC. | $123.41 | 2022 | |
| Vanda Pharmaceuticals INC. | $104.41 | 2024-2025 | Ponvory |
| Scilex Pharmaceuticals INC. | $101.27 | 2022-2025 | Ztlido |
| Celgene Corporation | $94.64 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $67.25 | 2022-2023 | Belsomra |
| Mallinckrodt Hospital Products INC. | $66.88 | 2022-2023 | Acthar |
| Merz Pharmaceuticals, LLC | $60.85 | 2023-2025 | Xeomin |
| Octapharma USA, INC. | $39.28 | 2025 | Panzyga |
| Sanofi-Aventis U.S. LLC | $38.95 | 2021-2024 | |
| Avion Pharmaceuticals | $38.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $34.77 | 2022 | |
| Ironshore Pharmaceuticals INC. | $34.35 | 2023-2024 | Jornay Pm |
| Almatica Pharma LLC | $32.17 | 2021 | |
| Springworks Therapeutics, INC. | $28.21 | 2025 | Gomekli |
| Sumitomo Pharma America, INC. | $27.41 | 2024 | Aptiom |
| Tg Therapeutics, INC. | $22.07 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.79 | 2022 | |
| Currax Pharmaceuticals LLC | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.